Oral Immunotherapy Improves the Quality of Life of Adults with Food Allergy

Overview

Journal Allergy Asthma Clin Immunol

Specialty Allergy & Immunology

Date 2024 Oct 14

PMID 39402617

Authors

Naama Epstein-Rigbi

Michael B Levy

Liat Nachshon

Yael Koren

Michael R Goldberg

Arnon Elizur

Affiliations

Soon will be listed here.

Abstract

Background: Oral immunotherapy (OIT) has become the standard of care for children with food allergy (FA) and has substantially improved their quality of life. The effect of OIT on the quality of life in adults, however, has been studied to a much lesser degree.

Methods: Patients with food allergy aged ≥ 18 years who underwent OIT at Shamir Medical Center completed the Food Allergy Quality of Life Questionnaire-Adult Form (FAQLQ-AF) before and at the end of treatment. Adults with FA not undergoing OIT who completed the FAQLQ-AF at 2 time points, served as controls.

Results: A total of 44 adults, median age 23.4 years, who underwent OIT for milk (n = 19), egg (n = 2), peanut (n = 9), sesame (n = 6), and tree nuts (n = 8), and 11 controls were studied. The median OIT starting dose was 23.8 mg protein. 33 patients (75%) reached full desensitization within a median of 10.3 months. The FAQLQ-AF baseline scores were comparable between the study and control groups for all items except for Food Allergy related Health (FAH) item in which the study group had a significantly better score (p = 0.02). At the second time point, the study group had significantly better scores in all items (Allergen Avoidance and Dietary Restrictions (AADR), p = 0.02; and Emotional Impact (EI), Risk of Allergen Exposure (RAE), FAH and the Total Score, p < 0.01). The change in scores for the study group was significantly better, statistically and clinically, in AADR, p = 0.04; EI, p < 0.01; RAE, p = 0.01, and in the total score, p = 0.01.

Conclusions: OIT significantly improves quality of life of adults with FA. This finding adds important support for providing OIT in this population.

References

Nachshon L, Schwartz N, Elizur A, Schon Y, Cheryomukhin M, Katz Y . The Prevalence of Food Allergy in Young Israeli Adults. J Allergy Clin Immunol Pract. 2019; 7(8):2782-2789.e4. DOI: 10.1016/j.jaip.2019.05.046. View

Patel G, Kellner E, Clayton E, Chhiba K, Alakija O, Bryce P . Quality of life is lower in adults labeled with childhood-onset food allergy than in those with adult-onset food allergy. Ann Allergy Asthma Immunol. 2021; 127(1):70-75.e2. PMC: 8483056. DOI: 10.1016/j.anai.2021.03.009. View

Levy M, Elizur A, Goldberg M, Nachshon L, Katz Y . Clinical predictors for favorable outcomes in an oral immunotherapy program for IgE-mediated cow's milk allergy. Ann Allergy Asthma Immunol. 2013; 112(1):58-63.e1. DOI: 10.1016/j.anai.2013.10.001. View

Blumchen K, Trendelenburg V, Ahrens F, Gruebl A, Hamelmann E, Hansen G . Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy. J Allergy Clin Immunol Pract. 2018; 7(2):479-491.e10. DOI: 10.1016/j.jaip.2018.10.048. View

Stensgaard A, Bindslev-Jensen C, Nielsen D, Munch M, DunnGalvin A . Quality of life in childhood, adolescence and adult food allergy: Patient and parent perspectives. Clin Exp Allergy. 2016; 47(4):530-539. DOI: 10.1111/cea.12849. View

Peters R, Krawiec M, Koplin J, Santos A . Update on food allergy. Pediatr Allergy Immunol. 2020; 32(4):647-657. PMC: 8247869. DOI: 10.1111/pai.13443. View

Epstein-Rigbi N, Levy M, Nachshon L, Koren Y, Katz Y, Goldberg M . Efficacy and safety of food allergy oral immunotherapy in adults. Allergy. 2022; 78(3):803-811. DOI: 10.1111/all.15537. View

Elizur A, Appel M, Goldberg M, Yichie T, Levy M, Nachshon L . Clinical and laboratory 2-year outcome of oral immunotherapy in patients with cow's milk allergy. Allergy. 2015; 71(2):275-8. DOI: 10.1111/all.12794. View

van der Velde J, Flokstra-de Blok B, Vlieg-Boerstra B, Oude Elberink J, Schouten J, DunnGalvin A . Test-retest reliability of the Food Allergy Quality of Life Questionnaires (FAQLQ) for children, adolescents and adults. Qual Life Res. 2009; 18(2):245-51. DOI: 10.1007/s11136-008-9434-2. View

10.

Sicherer S, Warren C, Dant C, Gupta R, Nadeau K . Food Allergy from Infancy Through Adulthood. J Allergy Clin Immunol Pract. 2020; 8(6):1854-1864. PMC: 7899184. DOI: 10.1016/j.jaip.2020.02.010. View

11.

Nurmatov U, Dhami S, Arasi S, Pajno G, Fernandez-Rivas M, Muraro A . Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy. 2017; 72(8):1133-1147. DOI: 10.1111/all.13124. View

12.

Pajno G, Fernandez-Rivas M, Arasi S, Roberts G, Akdis C, Alvaro-Lozano M . EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2017; 73(4):799-815. DOI: 10.1111/all.13319. View

13.

Nachshon L, Goldberg M, Katz Y, Levy M, Elizur A . Long-term outcome of peanut oral immunotherapy-Real-life experience. Pediatr Allergy Immunol. 2018; 29(5):519-526. DOI: 10.1111/pai.12914. View

14.

Nowak-Wegrzyn A, Sato S, Fiocchi A, Ebisawa M . Oral and sublingual immunotherapy for food allergy. Curr Opin Allergy Clin Immunol. 2019; 19(6):606-613. DOI: 10.1097/ACI.0000000000000587. View

15.

Flokstra-de Blok B, van der Meulen G, DunnGalvin A, Vlieg-Boerstra B, Oude Elberink J, Duiverman E . Development and validation of the Food Allergy Quality of Life Questionnaire - Adult Form. Allergy. 2009; 64(8):1209-17. DOI: 10.1111/j.1398-9995.2009.01968.x. View

16.

Nachshon L, Goldberg M, Levy M, Appel M, Epstein-Rigbi N, Lidholm J . Efficacy and Safety of Sesame Oral Immunotherapy-A Real-World, Single-Center Study. J Allergy Clin Immunol Pract. 2019; 7(8):2775-2781.e2. DOI: 10.1016/j.jaip.2019.05.031. View

17.

Goossens N, Flokstra-de Blok B, Vlieg-Boerstra B, Duiverman E, Weiss C, Furlong T . Online version of the food allergy quality of life questionnaire-adult form: validity, feasibility and cross-cultural comparison. Clin Exp Allergy. 2011; 41(4):574-81. DOI: 10.1111/j.1365-2222.2011.03711.x. View

18.

Elizur A, Appel M, Nachshon L, Levy M, Epstein-Rigbi N, Koren Y . Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study). Allergy. 2022; 77(6):1863-1872. DOI: 10.1111/all.15212. View

19.

Hise K, Rabin R . Oral Immunotherapy for Food Allergy-a US Regulatory Perspective. Curr Allergy Asthma Rep. 2020; 20(12):77. DOI: 10.1007/s11882-020-00973-x. View

20.

Nachshon L, Goldberg M, Elizur A, Levy M, Schwartz N, Katz Y . A Web site-based reporting system for monitoring home treatment during oral immunotherapy for food allergy. Ann Allergy Asthma Immunol. 2015; 114(6):510-5. DOI: 10.1016/j.anai.2015.04.007. View